Augmentation of streptokinase-induced thrombolysis by heparin and prostacyclin.
The ability of heparin and prostacyclin to improve streptokinase-induced recanalization was examined in open-chest dogs subjected to thrombotic occlusion of the left circumflex coronary artery. Vessel injury was produced by electrical stimulation of the intimal surface at the site of a noncircumferential fixed stenosis. Animals were divided into three treatment groups as follows: group 1 received intracoronary streptokinase alone (75,000 units/80 min starting 30 min postocclusion; n = 8); group 2 received streptokinase plus heparin (300 units/kg i.v. at 20 min postocclusion; n = 7); group 3 received streptokinase plus heparin plus prostacyclin (500 ng/kg/min, intracoronary, given intermittently during reperfusion; n = 7). Overall, the groups did not differ with respect to preocclusion coronary blood flow (27 +/- 1 ml/min; +/- SEM), the duration of streptokinase infusion required to achieve reflow (15 +/- 2 min), and the percentage of animals recanalized (85%). They did differ in the average rate of reflow, which was greater in group 2 (16 +/- 2 ml/min) and group 3 (20 +/- 4 ml/min) as compared with group 1 (6 +/- 1 ml/min; p less than 0.05). The intermittent reocclusions which persisted during reperfusion in group 1 and 2 dogs were diminished during the periodic infusions of prostacyclin. Thrombus mass at the site of injury was comparable among groups. In contrast, distal circumflex thrombi, about twice the weight of the proximal mass, were observed in all group 1 dogs and were undetectable in group 2 and 3 animals. Transient improvements in contractile force during reperfusion were observed only with groups 2 and 3.(ABSTRACT TRUNCATED AT 250 WORDS)
W A
WA
Schumacher
E C
EC
Lee
B R
BR
Lucchesi
D000818:Animals; D001145:Arrhythmias, Cardiac / Q000503:physiopathology; D003327:Coronary Disease / Q000188:drug therapy* / Q000503:physiopathology; D004285:Dogs; D004357:Drug Synergism; D004558:Electric Stimulation; D011464:Epoprostenol / Q000627:therapeutic use*; D005343:Fibrinolytic Agents; D006321:Heart / Q000503:physiopathology; D006493:Heparin / Q000627:therapeutic use*; D008297:Male; D013300:Streptokinase / Q000627:therapeutic use*; D013997:Time Factors
D005343:Fibrinolytic Agents; D006493:Heparin; D011464:Epoprostenol; D013300:Streptokinase